Pick a time period -
No more available filters You need to apply a filter before selecting newsroom

Use our filters to get your customized news. Save and subscribe to as many filters as you want, get the news that YOU are interested in right in your mailbox, RSS feed or in your personalized dashboard. Share your stories, news, multimedia and pressreleases and get a wider audience with news.cision.com.

DOF Group ASA – Contract award

DOF is very pleased to announce a Large Contract with Equinor Energy for the AHTS Skandi Iceman. The award means that the DOF Group will have two anchor handlers supporting Equinor’s Norwegian operations until 2027 at the earliest with Skandi Vega having been on charter to Equinor since delivery 2010. This contract will build on the long-term relationship between the DOF Group and Equinor for AHTS services. The contract also includes ROV services provided by the DOF Group. Commencement will be Q2 2024 with 3-year firm and 3x1 year options.Mons Aase, CEO DOF Group ASA, said, “This award

Invitation to presentation of Sweco Group's Q4 and Year-end report

The Sweco Group's results for the fourth quarter and year-end report 2023 will be published on February 9 at approx. 07:20 CET.A web cast and telephone conference will be held following the release of the results, starting at 09:00 CET.  Åsa Bergman, President and CEO, and Olof Stålnacke, CFO will comment on the report. Webcast registration: Click here Conference call registration: Click here  Slides used in the presentation and the report will be available at

Read original

ABGSC to publish Q4 2023 Interim Report on 9 February

ABG Sundal Collier (“ABGSC”) will publish its Q4 2023 figures on 9 February 2024 at 08:00 CET. The report will be available on our corporate website www.abgsc.com. Webcast presentation CEO Jonas Ström will present the Q4 results through a webcast at 09:00 CET, followed by a Q&A session. The webcast presentation can be accessed through a web link or call-in details presented on our corporate website www.abgsc.com. For further information: Geir B. Olsen, CFO, +47 22 01 60 35 For media contacts: Anna Tropp, Head of Communications, +46 722 30 94 17

All-time high in QuickMIC® abstracts at ECCMID 2024

The diagnostics company Gradientech today announces that six QuickMIC® abstracts will be presented at the 34th European Congress of Clinical Microbiology & Infectious Diseases (ECCMID) in Barcelona, Spain 27-30 April 2024.ECCMID is the world’s premier meeting place for clinical microbiologists and infectious disease specialists, gathering over 14,000 delegates yearly. This year, a record 7,000+ abstracts have been submitted, setting the stage for an exceptional event in April. At ECCMID 2024, six different abstracts with data from independent European studies will demonstrate that

ASSA ABLOY sells PACA ascenseur in France to KONE

ASSA ABLOY has sold its elevator maintenance business PACA ascenseur (“PACA”) in France to KONE. PACA was part of the acquisition of agta record in 2020. PACA is an elevator maintenance business located in Southern France. PACA was founded in 1995 and has some 210 employees. Sales in 2022 amounted to about 30 MEUR. "I find it satisfying that with KONE, PACA and its employees and customers get a committed long-term owner, creating new opportunities for the future and I wish them every success,” says Nico Delvaux, President and CEO of ASSA ABLOY. "In line with our strategy, we

Oriola Corporation to publish its Financial Statements Release 2023 on 16 February 2024

Oriola Corporation  Investor news  2 February 2024 at 9:00 a.m. EET  Oriola Corporation to publish its Financial Statements Release 2023 on 16 February 2024   Oriola Corporation will publish its Financial Statements Release 2023 on Friday 16 February 2024 at around 8:30 a.m. EET. The Financial Statements Release will be available on Oriola’s website after the publication.  Welcome to join our results presentation  CEO Katarina Gabrielson and CFO Timo Leinonen will present the full-year results at a webcast meeting on the same day starting at 10.00 a.m. EET. The link to the

Year-end report 2023: The market continues to be divided

Peab Year-end report January – December 2023”The year 2023 was marked by a divided market. The dramatically diminished housing market affected Peab’s housing construction while public building construction, civil engineering and paving continued to develop well. This demonstrates the strength in our broad business model with its four business areas and local roots close to customers”, says Jesper Göransson, President and CEO of Peab. Summary according to segment reporting: October – December 2023 · Adjustment of operations, provisions, write-downs and restructuring for a total of

Transaction in Own Shares

    2 February 2024 Vesuvius plc Share Buyback Programme – Transactions in Own Securities   Vesuvius plc (the "Company") announces that it has purchased the following number of its Ordinary Shares of 10p each from Jefferies International Limited (the “Broker”), pursuant to the terms of its Share Buyback Programme announced on 4 December 2023:   +---------------------------------------------------------------+----------+|Date of purchase: |01/02/2024|+-----------------------------------------------------------

Mydecine Innovations Group Announces Director Resignation

  Mydecine Innovations Group Announces Director Resignation     VANCOUVER, British Columbia, 02 February 2024 (GLOBE NEWSWIRE) -- Mydecine Innovations Group Inc. (“Mydecine” or the “Company”) (CSE:MYCO) (AQSE:MYIG) (OTC:MYCOF) (FSE: 0NF0), a forefront biotechnology company dedicated to revolutionising mental health and addiction treatment, announces that Neil Stevenson-Moore has resigned as a director of the Company. The Company would like to thank Mr. Stevenson-Moore for his contributions to the Company and wishes him well in this future endeavors.   The

Electrolux Group Year-end report Q4 2023

Highlights of the full-year of 2023 · In full-year 2023, net sales were SEK 134,451m (134,880) and operating income excl. non-recurring items was SEK 414m (831). Earnings declined mainly due to lower volumes following the weaker market demand as well as intensified price pressure in North America. The Group-wide cost reduction and North America turnaround program progressed well, resulting in a positive year-over-year impact of approximately SEK 5.5bn. Highlights of the fourth quarter of 2023 · In the fourth quarter, net sales amounted to SEK 35,636m (35,769) and organic sales

Invitation to the presentation of John Mattson’s year-end report for 2023 on 16 February at 10:00 a.m. (CET)

Invitation by John Mattson to the webcast and the teleconference on16 February at 10:00 a.m. (CET) being held in conjunction with the publication of the company’s year-end report for 2023 at 8:00 a.m. (CET) the same date.Investors, asset managers, equity analysts, the press and other stakeholders are invited to participate in the presentation, where CEO Per Nilsson and acting CFO Eva Wiklund will comment on the results for January-December 2023. Following the presentation, it will be possible to ask questions. The presentation will be given in Swedish and can be followed live via the

Skanska hosted the CEO Alliance meeting at European Spallation Source (ESS) in Lund, Sweden

On February 1, 2024, Skanska hosted the CEO Alliance meeting at European Spallation Source (ESS) in Lund, Sweden. During the day, the CEOs of the member companies gathered to discuss joint strategies for sustainable business development and innovation, with the aim of accelerating the climate transition and increasing Europe’s industrial competitiveness.The CEO Alliance unites companies from a wide range of industries. The common denominator is their dedicated focus on how each industry can reduce its CO2 emissions in all scopes and create business models that can speed up the transition to

Fourth quarter and full year report, 2023: Continued growth with margin expansions

Fourth quarter · Sales of SEK 904 (855) million, an increase of 6%. In local currencies the growth was 5%. · Sales, in local currencies increased by 16% in APAC and 6% in EMEA, while sales in Americas decreased by 5%.  · Sales in local currencies increased by 1% in Consumables and 31% in Technologies, while sales in Genetic Services decreased by 2%. · Gross margin increased to 56.9% (54.2). · Operating income before depreciation and amortisation (EBITDA) was SEK 294 (273) million, giving an EBITDA margin of 32.5% (31.9). · Operating cash flow increased to SEK 171 million

Earnings Release TagMaster AB 2023

Press release, Sweden, Stockholm, 2 February 2024 Continued business focus and efficiency in combination with strategic acquisitions provide growth and profitability October-December 2023 · Net sales increased during the quarter by 19,7 % to 125,3 MSEK (104,6). The organic and currency adjusted growth amounted to 2,5 %. · Adjusted EBITDA increased during the quarter by 54,4 % and amounted to 22,7 MSEK (14,7) corresponding to an adjusted EBITDA margin by 18,1 % (14,0). · Operating profit was 7,3 MSEK (2,6), corresponding to an operating margin of 5,8 % (2,4). · Profit/

Publishing of YIT Corporation's Financial Statements Bulletin 2023 on 9 February 2024

YIT Corporation Investor News 2 February 2024 at 09:00 a.m.Publishing of YIT Corporation's Financial Statements Bulletin 2023 on 9 February 2024  YIT Corporation's Financial Statements Bulletin 2023 will be published on Friday, 9 February 2024 at approximately 9:00 a.m. Finnish time (EET, approx. 7:00 a.m. GMT). The stock exchange release and the reporting materials in Finnish and in English will be available at that time on the company's website at www.yitgroup.com/investors .  A webcast and an international telephone conference will be arranged

Clinical Laserthermia Systems AB enters into top down underwriting commitments in the ongoing exercise of warrants of series TO 6 B totaling SEK 7 million.

Lund, Sweden - Clinical Laserthermia Systems AB ("CLS" or the "Company") announces that the Company has agreed on underwriting commitments (so-called "top-down" or "top guarantee") in the ongoing exercise of warrants of series TO 6 B whose exercise period runs until February 6, 2024 ("TO 6 B"). The underwriting commitments comprises a total of SEK 7 million, corresponding to approximately 30 per cent of the issue proceeds that the Company can raise through the exercise of TO 6 B.In the ongoing exercise of TO 6 B, CLS has agreed on top down underwriting commitments with qualified investors.

Year-end report 1 January – 31 December 2023

Strong cash flow and significant actions to improve profitability within Medtech "Demand is healthy in the markets and segments where AddLife's companies operate. We can now summarize 2023 as a year with historically strong organic growth of 10%. In the fourth quarter, cash flow improved significantly and net debt decreased by approximately SEK 400 m. Labtech's profitability was high and in Medtech, profitability was generally good, but weighed down by AddVision and Homecare, where we are now implementing significant actions to improve profitability."Fredrik Dalborg, President and CEO

Elevating EdTech in Italy: Shape Robotics and CampuStore announce partnership

Shape Robotics announces a new strategic distribution agreement with CampuStore, Italy's foremost EdTech provider and the main e-commerce platform for education. The collaboration signifies a major milestone in Shape Robotics' expansion into the Italian market, leveraging CampuStore's extensive network in the educational sector. CampuStore has been a key player in the Italian education sector since 1994. With over 40,000 clients, including more than 7,700 schools and 800 universities, their impact is widespread. The collaboration comes at a time when Italy is heavily investing in

SBB's associated company PPI is investigating the possibility of an initial public offering and listing on the Oslo Stock Exchange

NOT FOR PUBLICATION, RELEASE OR DISTRIBUTION, IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, IN OR INTO AUSTRALIA, CANADA, THE HONG KONG SPECIAL ADMINISTRATIVE REGION OF THE PEOPLE'S REPUBLIC OF CHINA, JAPAN, SOUTH AFRICA, OR THE UNITED STATES, OR ANY OTHER JURISDICTION IN WHICH THE DISTRIBUTION OR RELEASE WOULD BE UNLAWFULSamhällsbyggnadsbolaget i Norden AB (publ) ("SBB")'s associated company Public Property Invest AS ("PPI") prepares for a possible initial public offering and listing on the Oslo Stock Exchange (the "IPO"). SBB owns 44.8 percent of the shares in PPI. As of June 30, 2023,

Konecranes Plc’s Financial statement release 2023: All-time high sales and comparable EBITA margin in 2023

KONECRANES PLC FINANCIAL STATEMENT RELEASE 2023 FEBRUARY 2, 2024 8:30 am EET   Konecranes Plc’s Financial statement release 2023: All-time high sales and comparable EBITA margin in 2023   All-time high sales and comparable EBITA margin in 2023   This release is a summary of Konecranes Plc’s Financial statement release 2023. The complete report is attached to this release in pdf format and is also available on Konecranes’ website at www.konecranes.com.   The figures presented in this report are unaudited. Figures in brackets, unless otherwise stated, refer to the same

Proposals of the Nomination Committee of the Board of Directors to Fiskars Corporation’s Annual General Meeting 2024

Fiskars CorporationStock exchange releaseFebruary 2, 2024 at 8.30 a.m. EET Proposals of the Nomination Committee of the Board of Directors to Fiskars Corporation’s Annual General Meeting 2024 The Nomination Committee of the Board of Directors of Fiskars Corporation presents the following proposals to the Annual General Meeting to be held on March 13, 2024. The proposals will be included in the notice to the Annual General Meeting to be published at a later date. Resolution on the remuneration of the members of the Board of Directors The Nomination Committee of the Board of

Hansa Biopharma Year-end report January-December 2023

· Strong revenue generation in Q4 2023 including SEK 43m in Idefirix® product sales supported by growth in new markets such as U.K., Germany, and Spain · Encouraging results from first-in-human trial of HNSA-5487 · Initiation of phase 1b trial of imlifidase as pre-treatment to Sarepta’s SRP-9001 in DMDLund, Sweden, February 2, 2024, Hansa Biopharma, the pioneer in immunomodulatory enzyme technology for rare IgG mediated diseases, today announced its business update and year-end report for January to December 2023. Highlights for the fourth quarter of 2023 · Strong commercial

Year-end report January-December 2023

Stable results and strong cash flow in the quarter Fourth quarter 2023 – Net sales increased by 8.0 percent to SEK 7,135 million (6,609) – Organic growth adjusted for calendar effects was 5.9 percent (11.3)   – EBITA, excl. items affecting comparability, was SEK 596 million (578) – EBITA margin, excl. items affecting comparability, was 8.4 percent (8.8) – EBITA totalled SEK 541 million (562) – EBITA margin was 7.6 percent (8.5) – EBIT (operating profit) amounted to SEK 501 million (527) – Basic earnings per share: SEK 2.77 (3.51) January–December 2023 – Net

YEAR-END REPORT JANUARY - DECEMBER 2023

Improved operating margin and strong cash flow for the year Fourth quarter 2023 · Net sales decreased by 17% to SEK 8,605m (10,353). Changes in exchange rates impacted with -1%. Planned exits of low-margin petrol-powered business impacted with -2%. · Organic sales declined by 15%. · Operating income was SEK -983m (-1,737) and the operating margin was -11.4% (-16.8). · Excluding items affecting comparability, the operating income amounted to SEK -168m (-13) and the operating margin was -1.9% (-0.1). · Items affecting comparability amounted to SEK -815m (-1,724), and was

There are no items matching the current filter
There are no more items matching the current filter
Back to top